Genprex Issues Stockholder Letter and Provides 2025 Corporate Update

Core Viewpoint - Genprex, Inc. has achieved significant clinical development milestones in 2025, focusing on advancing its gene therapy programs for cancer and diabetes, with ongoing clinical trials for lung cancer treatments [1][2]. Group 1: Company Achievements - The company has issued a stockholder letter summarizing recent achievements and outlining key milestones for 2025 and beyond [1]. - Genprex's lead product candidate, Reqorsa® Gene Therapy, is currently being evaluated in two clinical trials for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), both of which have received Fast Track Designation from the FDA [3]. - The SCLC program has also received Orphan Drug Designation from the FDA, indicating its potential to address unmet medical needs [3]. Group 2: Technology and Approach - Genprex utilizes a systemic, non-viral Oncoprex® Delivery System that encapsulates gene-expressing plasmids in lipid-based nanoparticles, administered intravenously to target tumor cells [3]. - The diabetes gene therapy approach involves a novel infusion process using an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas, aiming to transform alpha cells into functional beta-like cells capable of producing insulin [3]. Group 3: Future Outlook - The company is focused on executing upcoming milestones in the second half of 2025 and beyond, with a commitment to transforming the lives of patients battling cancer and diabetes through innovative gene therapies [2].